The global mRNA vaccines and therapeutics market size is estimated at USD 2.14 billion in 2025 and is predicted to reach around USD 21.97 billion by 2034, accelerating at a CAGR of 29.71% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: MRNA Vaccines and Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Disease Type
8.1.1 Hereditary Transthyretin-mediated Amyloidosis Genetic
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Acute Hepatic Porphyria
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Primary Hyperoxaluria Type 1
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Atherosclerotic Cardiovascular Disease
8.1.4.1. Market Revenue and Volume Forecast
9.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by Route of Administration
9.1.1. IV Infusion
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Volume Forecast
10.1. MRNA Vaccines and Therapeutics Market Revenue and Volume, by End-user Type
10.1.1. Research Institutes
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Hospitals and Clinics
10.1.2.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Disease Type
11.1.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.3. Market Revenue and Volume Forecast, by End-user Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Disease Type
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.4.3. Market Revenue and Volume Forecast, by End-user Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Disease Type
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.5.3. Market Revenue and Volume Forecast, by End-user Type
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Disease Type
11.2.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.3. Market Revenue and Volume Forecast, by End-user Type
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Disease Type
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.4.3. Market Revenue and Volume Forecast, by End-user Type
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Disease Type
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.5.3. Market Revenue and Volume Forecast, by End-user Type
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Disease Type
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.6.3. Market Revenue and Volume Forecast, by End-user Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Disease Type
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.7.3. Market Revenue and Volume Forecast, by End-user Type
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Disease Type
11.3.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.3. Market Revenue and Volume Forecast, by End-user Type
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Disease Type
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.4.3. Market Revenue and Volume Forecast, by End-user Type
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Disease Type
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.5.3. Market Revenue and Volume Forecast, by End-user Type
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Disease Type
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.6.3. Market Revenue and Volume Forecast, by End-user Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Disease Type
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.7.3. Market Revenue and Volume Forecast, by End-user Type
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Disease Type
11.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.3. Market Revenue and Volume Forecast, by End-user Type
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Disease Type
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.4.3. Market Revenue and Volume Forecast, by End-user Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Disease Type
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.5.3. Market Revenue and Volume Forecast, by End-user Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Disease Type
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.6.3. Market Revenue and Volume Forecast, by End-user Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Disease Type
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.7.3. Market Revenue and Volume Forecast, by End-user Type
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Disease Type
11.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.3. Market Revenue and Volume Forecast, by End-user Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Disease Type
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.4.3. Market Revenue and Volume Forecast, by End-user Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Disease Type
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.5.3. Market Revenue and Volume Forecast, by End-user Type
12.1. Kernal Biologics Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Argos Therapeutics Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Charoen Pokphand Group
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AIM Vaccine Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CureVac SE
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Ethris GmbH
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bohringer Ingelheim International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Arcturus
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Daiichi Sankyo
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample